Table 2. Comparison of body weight, blood samples and intimal hyperplasia assessed by OCT.
| Parameter | At baseline | At 40 weeks | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Sham group (n=3) | LGV group (n=5) | HGV group (n=5) | P | Sham group (n=3) | LGV group (n=5) | HGV group (n=5) | P | ||
| Body weight (kg) | 36.00±1.00 | 35.70±2.22 | 34.90±1.52 | 0.66 | 41.00±2.00 | 59.40±4.04* | 60.50±4.88* | <0.001 | |
| Fasting BG (mmol/L) | 4.37±0.88 | 4.28±0.57 | 3.78±0.76 | 0.45 | 4.38±0.45 | 10.19±1.20* | 10.01±1.84* | <0.001 | |
| Total cholesterol (mmol/L) | 1.94±0.08 | 2.14±0.36 | 2.29±0.25 | 0.27 | 2.47±0.04 | 4.96±1.15* | 5.11±1.97* | 0.06 | |
| LDL-C (mmol/L) | 0.77±0.46 | 0.87±0.11 | 0.99±0.22 | 0.36 | 1.48±1.15 | 4.39±1.02* | 4.55±1.55* | 0.02 | |
| HDL-C (mmol/L) | 1.66±0.02 | 1.62±0.10 | 1.60±0.18 | 0.78 | 1.15±0.07 | 1.04±0.61 | 1.10±0.38 | 0.94 | |
| Triglycerides(mmol/L) | 0.41±0.33 | 0.21±0.09 | 0.32±0.23 | 0.45 | 0.60±0.10 | 1.66±0.80* | 1.68±0.43* | 0.05 | |
| Mean of BG (mmol/L) | NA | NA | NA | NA | 6.10±0.26 | 12.80±1.68* | 13.06±1.03* | <0.001 | |
| SD of BG (mmol/L) | NA | NA | NA | NA | 1.37±0.15 | 2.46±0.21*# | 3.34±0.11*# | <0.001 | |
| OCT analysis | |||||||||
| Lumen area (mm2) | NA | NA | NA | NA | NA | 4.32±0.75 | 3.00±0.37# | <0.001 | |
| Stent area (mm2) | NA | NA | NA | NA | NA | 4.85±0.64 | 4.95±0.69 | 0.481 | |
| Neointimal area (mm2) | NA | NA | NA | NA | NA | 0.53±0.19 | 1.95±0.85# | <0.001 | |
| Percent area stenosis (%) | NA | NA | NA | NA | NA | 0.11±0.05 | 0.38±0.12# | <0.001 | |
| NIT (mm) | NA | NA | NA | NA | NA | 0.15±0.04 | 0.35±0.05# | <0.001 | |
Data are presented as the mean ± standard deviation. *P<0.05, compared with sham group; #P<0.05, compared with LGV group. OCT, optical coherence tomography; LGV, low glycemic variability; HGV, high glycemic variability group; BG, blood glucose; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; SD, standard deviations; NIT, neointimal thickness.